A new report by congressional Democrats reveals a sharp rise in pharmaceutical stock holdings by a former president, surging from a peak of $1.7 million in 2024 to as much as $56.2 million by the end of 2025. The findings highlight a significant increase in value over the span of a year, raising questions about financial interests during a period of political influence. The report does not specify the exact source of the growth but underscores the scale of the change. Details on how these holdings may relate to policy decisions or public statements remain under scrutiny.
The report from congressional Democrats found that Trump's pharmaceutical stock holdings grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025.
